Treatment ends. The rebuilding doesn't happen automatically. This is the protocol for after.

“Bower JE et al.'s research on cancer-related fatigue (JAMA Oncology, 2014) established that chemotherapy-induced fatigue is mechanistically distinct from ordinary tiredness — it is driven by pro-inflammatory cytokines (IL-6, TNF-α), HPA axis dysregulation, and mitochondrial dysfunction that persist for months or years after treatment ends. Sestak I et al. documented that women with chemotherapy-induced amenorrhea lose bone density at a rate of 5–10% annually in the first years post-treatment — far faster than natural menopause. Both findings point to the same protocol priorities: anti-inflammatory support, mitochondrial restoration, and bone-protective nutrition. Safety is the first protocol: this stack explicitly excludes all phytoestrogens, adaptogens with estrogenic activity, and compounds with uncertain safety profiles in hormone-sensitive cancer.”

Bower JE et al., JAMA Oncology, 2014 — inflammation and cancer-related fatigue

“After chemo for breast cancer at 44, I went into menopause overnight. The bone density loss, the fatigue, the brain fog — it hit all at once. I researched every ingredient in The After carefully before starting anything, and I cleared the whole list with my oncologist. She approved everything and said the D3 and omega-3 were exactly what she'd have recommended anyway. I always run these things by her first — that's non-negotiable.”